Holen Sie sich die Stockscreener-App
0.45
1.98%
-0.0091
Handel nachbörslich:
.45
Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten
How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals - Yahoo Finance
Inflation Data: Is Sangamo Therapeutics Inc stock positioned well for digital economy2025 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - moha.gov.vn
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - Zenopa
Is Sangamo Therapeutics Stock Built to Withstand a Pullback? - Trefis
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - MSN
Why analysts recommend Sangamo Therapeutics Inc. (GBY) stockQuarterly Earnings Summary & Precise Buy Zone Identification - Newser
Will Sangamo Therapeutics Inc. (GBY) stock maintain strong growthBreakout Watch & Real-Time Buy Signal Alerts - Newser
Sangamo Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript - GuruFocus
Can Sangamo Therapeutics Inc. (GBY) stock attract analyst upgrades2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - Newser
Can Sangamo Therapeutics Inc. (GBY) stock reach $200 price targetPortfolio Gains Report & Low Risk High Win Rate Stock Picks - Newser
How reliable is Sangamo Therapeutics Inc. (GBY) stock dividend growth2025 Momentum Check & Expert Curated Trade Setup Alerts - Newser
How Sangamo Therapeutics Inc. (GBY) stock reacts to fiscal policiesQuarterly Trade Review & Capital Efficient Trading Techniques - Newser
SGMO SEC FilingsSangamo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
FDA grants fast track designation for Sangamo’s pain treatment By Investing.com - Investing.com Canada
How Sangamo Therapeutics Inc. (GBY) stock performs in volatility spikesMarket Growth Report & Expert Approved Momentum Trade Ideas - Newser
Sangamo Therapeutics (SGMO) Stock: Gains FDA Fast Track for ST-503 in SFN Pain Treatment - parameter.io
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 29% Price Drop - 富途牛牛
Sangamo Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - marketscreener.com
Sangamo Therapeutics (SGMO) Surges on FDA Fast Track Designation for ST-503 - GuruFocus
Sangamo (SGMO) Gains FDA Fast Track for Chronic Pain Treatment - GuruFocus
Sangamo Therapeutics secures FDA fast track for ST-503 - Traders Union
Sangamo Therapeutics receives U.S. FDA fast track designation for ST-503 - marketscreener.com
Sangamo Therapeutics (Nasdaq: SGMO) gets FDA Fast Track for ST-503 in small fiber neuropathy - Stock Titan
Sangamo Therapeutics (SGMO) Stock Analysis Report | Financials & Insights - Benzinga
Is Sangamo Therapeutics Inc. (GBY) stock a top hedge fund pick2025 Technical Patterns & High Yield Stock Recommendations - Newser
Earnings Report: Is Sangamo Therapeutics Inc. stock attractive for retirement portfolios2025 Top Gainers & Capital Efficient Trading Techniques - BỘ NỘI VỤ
Sangamo Therapeutics Q3 2025 Earnings Preview - MSN
Sangamo Therapeutics, Inc. (GBY.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
How Recent Developments Are Rewriting the Story for Sangamo Therapeutics - Yahoo Finance
With Sangamo Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
[Form 4] SANGAMO THERAPEUTICS, INC Insider Trading Activity - Stock Titan
SGMO Form 4: CEO RSU vesting and 2.05M shares owned - Stock Titan
SGMO insider reports RSU tax withholding, 696,718 shares owned - Stock Titan
What drives Sangamo Therapeutics Inc. (GBY) stock priceCandlestick Trading Patterns & High Return Investment Ideas - earlytimes.in
Sangamo rises as FDA accepts rolling submission request for gene therapy - MSN
Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive - simplywall.st
What analysts say about Sangamo Therapeutics Inc GBY stockDividend Yield Trends & The Smart Money Is Buying These Picks - earlytimes.in
Sangamo Therapeutics, Inc. (SGMO) Stock: Soars 9.95% on FDA Milestone for Gene Therapy - parameter.io
With cash running low, East Bay biotech Sangamo bets on FDA submission strategySan Francisco Business Times - The Business Journals
Sangamo Therapeutics Gets US FDA Approval to Begin Rolling BLA Submission for Fabry Gene Therapy - marketscreener.com
Sangamo Therapeutics (SGMO) Advances Fabry Disease Therapy with FDA Rolling Submission - GuruFocus
Sangamo (SGMO) Advances Gene Therapy for Fabry Disease with FDA Approval Process - GuruFocus
FDA accepts Sangamo’s rolling BLA submission for Fabry disease gene therapy - Investing.com Canada
Sangamo Therapeutics announces FDA acceptance of BLA rolling submission request - marketscreener.com
Sangamo Therapeutics Announces FDA Acceptance of Rolling Submission for Gene Therapy ST-920 for Fabry Disease Treatment - Quiver Quantitative
Sangamo stock climbs after FDA accepts BLA rolling submission request By Investing.com - Investing.com Canada
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease - The Manila Times
Sangamo (Nasdaq: SGMO) rolling ST-920 Fabry BLA accepted by FDA for accelerated review - Stock Titan
Will Sangamo Therapeutics Inc. (GBY) stock rise with strong economyWeekly Trend Report & Verified Technical Trade Signals - newser.com
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Will Sangamo Therapeutics Inc. (GBY) stock gain from green policiesQuarterly Investment Review & Safe Entry Trade Reports - newser.com
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):